All News

mRNA (Messenger ribonucleuc acid) technology has been thrust into the limelight in recent months, with the platform proving to be the springboard for two approved vaccines against the SARS-CoV-2 virus.

The $35 million investment will more than double the site’s batch-size scaling and product output.

New site in Cardiff boosts the company's production capacity for equipment crucial in the supply chain for mRNA vaccines production

Firms say the partnership will "multiply the power of both companies, the pharmaceutical industry and the medical cannabis industry"

The capital will be used to expand and industrialise the company's range of single-use bioreactor systems and contract process development services

COVID-19 has focused a spotlight on the ability of mRNA technology to accelerate vaccine development and approval. That same technology can hasten the development and approval of other therapeutic classes, including cancer immunotherapy, protein replac...

The solid oral dose specialist signs letter of intent for acquisition of a CDMO providing a full range of services

The new facility will provide access to domestically manufactured vaccines against respiratory viruses

Innovation is the cornerstone of the drug delivery technology sector; efforts to make therapies more convenient for patients, reduce side effects and differentiate products from the competition have always made the delivery sector a hotbed of new ideas...

The CPHI North America exhibition is taking place in-person this week in Philadelphia from 10-12 August. Here we take a look at key learnings from the past two weeks of expert-led content, available to all attendees as part of the hybrid event experien...

KYOWA Pharmaceutical Industry will be the CDMO's first Japanese client for its Zhunan manufacturing site

The expansion is Heraeus’ response to increasing global demand for these products in cancer treatment

Dependence on Asia – and specifically China – has been the subject of a great deal of attention by political and industry leaders in the last year. In North America, this has led to calls to “reshore” drug production to domestic facilities.

Watch this Learning Lab video presented by Chris McPherson, Principal Scientist, DS Manufacturing, Samsung Biologics, which details how CDMOs have reacted to the challenging ‘Black Swan’ event that is the COVID-19 pandemic by initiatin...

The cosmetics packaging sector will need to respond to increasing consumer awareness of climate change by transitioning from fossil-based materials to long-term carbon neutral and carbon negative alternatives, according to industry experts speaking at ...

Tech transfer is a crucial phase that converts clinical promise into commercial gain but pressure on sponsors to reduce time to market in the age of COVID-19 means CDMOs have to be on top of their game to deliver. What are the latest innovations to sol...

The collaboration will see Catalent install a commercial-scale KinetiSol technology manufacturing line at its Somerset, New Jersey, facility

The purchase of BMS's Couvet, Switzerland facility adds commercial-scale production capacity for capsule and tablet dosage forms

Explore the series of Learning Labs at CPHI North America in which thought leaders at our exhibitors showcase their extensive knowledge on all areas of the pharma supply chain, offering industry insights across drug manufacturing, outsourcing, pharma i...

The new approval of Semeglee allows pharmacy-level substitution for Lantus across the US

Explore the series of Learning Labs at CPHI North America across several product innovation categories in which thought leaders at our exhibitors showcase their extensive expertise in all areas of the pharma supply chain, offering industry insight...

Opportunities for contract development and manufacturing organisations (CDMOs) in China continue to grow but many questions remain over what the future of the sector will look like in the world's second largest pharmaceutical market.

CDMOs need to diversify and expand their capabilities to take full advantage of strong growth in prominent end markets such as small molecule, monoclonal antibodies and cell and gene therapy, according to an industry expert on a panel at the CPHI North...

Acquiring Xell AG will enable Sartorius to offer specialised media for manufacturing viral vectors

Speaking at CPHI North America, Dr Scott Gottlieb shares insights into how the US should prepare for future pandemics by building out vaccine capacities

Transformative technologies and the opportunities afforded by the COVID-19 pandemic have spurred investment in the life sciences outsourcing sector, according to a panel of industry experts speaking at CPHI North America on Monday.

Accelerated efforts align with the Paris Agreement and Race To Zero to combat climate change

The combined capabilities will offer flexibility and innovation from small-scale biosimilar development through to large-scale manufacturing

More than 350,000 health apps are currently available, increasingly focused on helping them manage their conditions rather than on wellness management

The rise in the concept of ‘self-care’ has forced the beauty and cosmetics industry to think differently about how they launch their products. Martin Oxley, Managing Director at buzzback explains why the cosmeceuticals sector does not just ...

As more and more companies operating in the pharmaceutical space are moving into cosmetics, the temptation is to think that life will be much easier from a regulatory and compliance perspective.

Two 2,000-liter single-use bioreactors to be installed as part of first phase expected to be operational in April 2023

The investment will fund the construction of a Translational Science Center for its Healthcare business sector, as well as a new Learning Center

The acquisition will add manufacturing footprint in the US enabling the company to develop its pipeline of novel cancer product candidates

Samsung to provide end-to-end CDMO services to advance Kineta's novel anti-VISTA antibody for the treatment of solid tumours

Cannabinoids have caught the attention of Pharma and Cosmetic companies alike in recent years, celebrated for their anti-inflammatory, anti-oxidant and anti-bacterial properties in cosmetic products, and neurological and chronic pain benefits on the ph...

Using Veratrak's platform, the CDMO will have full oversight of data, including an audit trail of data and document processes

67,000-square-foot facility at Carlsbad campus is part of CDMO's investment strategy that addresses growing global demand for cell and gene therapies and vaccines

Acquisition will add West Coast coverage to the CDMO's East Coast and European capabilities and enhance its biologics formulation development and fill-finish network

The company will use its orally disintegrating tablet technology Zydis for JOS Pharmaceuticals' licensed CBD product

The emerging biotech company unveils plans for a 1.2 million-sq. ft manufacturing facility in Yangzhou

China-based company could supply up to 380 million doses from July 2021 through to June 2022

The integrated CDMO rolls out services to the broader community of drug manufacturers and developers

Healthcare provision is constantly evolving. Whereas in the past, decision making on treatments for patients was very much the domain of physicians and doctors, patients now feel more empowered to be involved in the decision making process. The healthc...

A new media panel, gene kit and advanced resins help reduce manufacturing costs and increase the viability of gene therapies

The CDMO plans to roll out the ISO 45001 and ISO 14001 certification throughout multiple sites worldwide

Pharma firm tells FDA tech transfer to its own facility in Schaftenau, Austria is underway after regulator highlighted concerns about third party CDMO site in Italy

Biogen’s Alzheimer’s drug Aduhelm has recently secured FDA approval to much fanfare. But do the benefits of the treatment justify the weighty $56,000 per year price tag?

For pharma manufacturers and service providers, attending face-to-face events and exhibitions has always been a crucial tool for meeting existing clients, signing contracts, and gathering leads for new business. But with events unable to trade over the...

Watch this CPHI Webinar sponsored by PharmaVentures, in which a broad panel of experts across the pharmaceutical manufacturing space discussed how M&A activity is being shaped by this ever evolving and complex sector

Move is part of US$500 million five-year investment programme by Moroccan government and consortium to establish vaccine and biotherapeutic manufacturing capacity in the country

Medalchemy facility now fully licensed to import, cultivate, extract, manufacture and export medical cannabis flower and extracts

The CDMO's fivefold capacity increase will provide early preclinical through to commercialisation support

Greenfield construction of the new facility is expected to start later this year

As part of $850 million investment package, CDMO will double US cell culture production for recombinant vaccines and increase UK gene therapy production tenfold

Facility is expected to come online in 2024 and will feature testing laboratories, manufacture of active pharmaceutical ingredients and manufacture and packaging of solid dosage pharmaceuticals and sterile products

The company will invest €400 million per year to advance mRNA technology beyond the pandemic

The expansion of mid-scale capacity will enable the company to offer a smooth transition between early-phase and large-scale commercial production

This month we discuss what is driving M&A strategies in the pharma space, paying particular attention to how investors regard the potential for the growing but fragmented CDMO sector

Ahead of the return of CPHI North America, Informa Markets has commissioned an in-depth report into the US pharma market focusing on how the pandemic has affected public discourse and political priorities, and how it could alter the pharmaceutical supp...

The investment will provide capacity to support current and future demands for the rapidly evolving cell and gene therapy sector

Carol Helena Aguilar Rodríguez – Pharmaceutical Chemist, Procaps SA Carolina Quintero Ochoa – PhD Polymer Science and Engineering, Procaps SA

Catch up on the latest trends and developments in patient centric drug development

IHL-216A may make sports safer and reduce the morbidity and mortality rates of people suffering serious head traumas

The agreement marks the second cell line development collaboration between the two companies

The expansion close to company's Martinsried headquarters includes a lyophilisation development centre for advanced therapy medicinal products

The market for CBD is growing and it is not just the pharmaceutical industry that is exploring its potential. Martin Oxley, MD at buzzback UK explains how consumer interest in plant-based ingredients and natural products present huge opportunities for ...

Dr. Paul Lohmann® recently received a CEP (Certificate of Suitability to the European Pharmacopoeia) for Monosodium Phosphate 2-hydrate, which enables a customer to register a drug in several countries in a cost-saving and simplified way. Since thi...

Ahead of Pharmapack Europe 2021 in October, we talk to one of the speakers, Serkan Oray, Vice President, Devices, Packaging & Wearable Technologies at UCB Pharma about the company's new electromechanical injection device and the innovation drive wi...

While the COVID-19 pandemic has created even greater demand for partnerships, CDMOs need to be aware that the needle has shifted, creating both opportunities and challenges and changing how the services industry does business

While in the past, much of the discussion around sustainability in the pharmaceutical industry rightly focused on efforts to minimize the environmental impact of drug production, the needle has now shifted. There are signs that companies not only under...

The company expects to complete its building and modernising plans in Turku by 2025

Drug categories impacted by travel restrictions expected to see higher sales levels in FY22

The French CDMO is also creating a new global resource for drug developers of ATMPs

During CPHI Discover (17th-28th May, 2021) – global pharma’s largest ever virtual gathering – we spoke with Doug Hausner, Senior Manager Continuous Manufacturing at Thermo Fisher Scientific. He presented his views on how continuous ma...

XDC will provide a full range of development and manufacturing services in one centralised region

Biogen and Eisai's Aduhelm approved using the accelerated approval pathway after clinical trials demonstrated it reduced amyloid beta plaques by up to 71%

The CDMO will also provide IND filling support for KAHR's drug candidate DSP502

The expanded capacity and capabilities include the development of a dedicated Life Sciences Technology Center

New $30 million manufacturing facility in Burlington, Ontario, will allow company to manage R&D in-house and scale production without reliance on third-party manufacturers

The initial outbreak of the COVID-19 pandemic delayed merger and acquisitions in the pharma sector, but evidence points to an uptick in activity because the rationale for sealing deals hasn’t changed

CPHI Discover (May 17-28) gave Pharma companies, suppliers and service providers the opportunity to keep potential buyers and partners abreast of the latest news, product information and market trends in the form of free-to-access, downloadable content...

Alliance to Zero aims to facilitate the transition of the pharma sector to reach net zero emissions target

Drug substance production line expected to be operational by end of 2021 as part of CDMO’s expanded collaboration with biotech

Cytokine storm is a main cause of worsening and death of COVID-19 patients. Techpool UTI inhibits the release of Inflammatory Cytokines and blocks Cytokine Storm in time to treat COVID-19 patients.

Hameln plant which provides fill and finish for Pfizer-BioNTech COVID-19 shot should be fully operational within the week, CDMO says

The additional manufacturing suite at the CDMO's Songdo site is anticipated to be ready for cGMP operations within the first half of 2022

A new location in Raleigh-Durham, North Carolina, close to the CDMO's Center of Excellence, will double its current footprint

The specialist CDMO receives manufacturing licenses from Switzerland and Denmark to supply customers with live biotherapeutic medicines

The latest coronavirus updates and developments impacting the global pharmaceutical supply chain (continued from here)

The company's new synthetic cholesterol product will help meet the demand for mRNA vaccines, including Pfizer-BioNTech Covid-19 Vaccine

The expansion will accelerate the progression and tech transfer of projects within the early clinical development phases

The purchase is part of $17 million capacity expansion, which is in addition to a wider $43 million investment into the company's Pennsylvania operations

The CDMO will support the production of hundreds of millions of doses from its facility in Incheon, South Korea.

CPHI Discover webinar examines the progress made so far in terms of vaccine distribution to the global population as well as anticipating future challenges

CPHI Discover panel of industry experts discusses impact of COVID-19 on API manufacturing and trading as well as the controversial topic of reshoring production

Upstream raw materials suppliers seen as the main source of innovation in a growing industry driven by demand for more natural ingredients manufactured in clean, sustainable way

Bookmark this page for regular updates on the rich variety of content coming your way via CPHI Discover, pharma’s largest ever virtual gathering, over the course of our three-day agenda

Partnering with one of northern Europe’s oldest academic universities, Lund University in Sweden, Pharmapack has launched this three-part podcast series, delivering the latest insights on medication packaging innovation and the gathering momentum...

Extending its patient-centric BD Intevia™ Disposable Autoinjector platform, BD builds on past successes while meeting the requirements of new, highly viscous, high-volume biologics for chronic diseases

Dosing complexity means programmable devices need to address several requirements around wearability and flexibility, CPHI Discover delegates are told

Pre-fillable syringes for intravenous drugs can replace traditional glass vials and ampoules, particularly in the time-sensitive and fast-paced world of emergency care

Novartis generics and biosimilars division will invest €150 million during the next 3-5 years at its Kundl, Austria and Palafolls, Spain sites while phasing out production of oral APIs at Les Franqueses site

Coronavirus pandemic has exacerbated manufacturing capacity constraints, particularly in injectable dose and viral vector production, CPHI audience told

Strong and effective partnerships with CDMOs are essential to success due to the complexity of manufacturing processes

Process of identifying new uses for approved drugs can be done through different pathways and can yield some surprising benefits

The UK’s withdrawal from the European Union has meant the pharmaceutical industry has had to adapt to some monumental changes in terms of research, regulatory affairs, and trade. In this CPHI Webinar, three industry experts discussed what the fut...

CDMO's site becomes the first vaccine production facility in South Korea to obtain EU GMP certification, allowing it to ship to Europe

Our virtual CPHI Discover event (17th-28th May) is just around the corner, full to the brim with three main content tracks. Here, we explore the major trends in APIs, Ingredients & Formulation

The plan includes the creation of more than 30 full-time jobs at the CDMO's Le Mans site

Our virtual CPHI Discover event (17th-28th May) is just around the corner, full to the brim with three main content tracks. Here, we explore the major trends in Drug Delivery and Packaging.

The CDMO's expertise and capabilities a "perfect fit" for overcoming the challenges of manufacturing this complex molecule

Our virtual CPHI Discover event (17th-28th May) is just around the corner, full to the brim with three main content tracks. Here, we explore the major trends and issues surrounding Manufacturing and Outsourcing.

New facility at Gosselies site will host commercial scale pDNA manufacturing as Catalent extends its cell and gene therapy footprint

Step inside our state-of-the-art plant to learn about our small molecules CDMO services and meet our team with a virtual tour that focuses on your areas of interest.

Read this new CPHI Trend Report which, via interviews with key industry experts, explores the state of India's API manufacturing issue and how it is being impacted by the country's ambitious healthcare reform programme as well as efforts by the governm...

In the future pharma companies will need to work closer with excipient companies if we are to develop better formulations more quickly

The addition of two new manufacturing trains will support the demand for high-value biopharmaceutical products

Industrial assets purchaser is offering high-capacity production line equipment formerly owned by bankrupt CMO

The expansion will support a 50% increase in production of biotech's COVID-19 vaccine at its manufacturing site